Left atrial enlargement with or without atrial fibrillation (AF), absence of valvular degeneration, and heart failure with preserved function have recently been identified as functional atrial mitral regurgitation (MR). This subtype of secondary MR currently appears to be underdiagnosed, and the need for treatment in the general population might be greater than predicted. The aim<a href="https://solaci.org/en/2022/05/30/europcr-2022-the-mitra-tune-registry-3/" title="Read more" >...</a>
Currently, the American and European guidelines recommend coronary angioplasty in patients with severe aortic stenosis with lesions >70% (Class IIa) who will undergo transcatheter aortic valve replacement (TAVR). However, the benefit of performing a revascularization in these patients is still uncertain. This prospective multicenter study included 2025 patients divided into two groups: complete revascularization (N = 1310)<a href="https://solaci.org/en/2022/05/24/europcr-2022-should-revascularization-be-performed-before-tavr-in-patients-with-stable-coronary-disease/" title="Read more" >...</a>
PCI success rate in chronic total occlusion (CTO), according to some registries, is below 80%. These failed revascularization procedures might lead to quality-of-life deterioration and shorter survival. This concern has driven the development of new techniques and technologies in an attempt to increase PCI success. Today, approximately 20% of CTOs are treated with a second<a href="https://solaci.org/en/2022/05/23/europcr-2022-the-improved-cto-trial-2/" title="Read more" >...</a>
TAVR is a valid alternative to treat failed surgical bioprosthetic valves, but one of its biggest challenges is patients with a small annulus. When using self-expanding valves, supra-annular implantation is recommended. However, at present, we only have retrospective, observational studies, not large enough. The LYTEN Trial is a randomized study in patients presenting failed bioprosthetic<a href="https://solaci.org/en/2022/05/23/europcr-2022-lyten-trial-v-in-v-in-small-annuli/" title="Read more" >...</a>
Patients undergoing TAVR are mostly older and more fragile, with comorbidities both cardiovascular and non-cardiovascular. Therefore, they are associated with thromboembolic and bleeding risk. This study looked mortality predictors after successful TAVR in the Galileo trial. Mortality at 248 days was 9.2%, 5.5% being of cardiovascular cause and 3.9% non-cardiovascular. Mortality predictors were age >85,<a href="https://solaci.org/en/2022/05/23/europcr-2022-galileo-trial-mortality-predictors-after-successful-tavr/" title="Read more" >...</a>
The presence of stroke after TAVR has dropped and is currently at 2%; however, it is 5 times more deadly, has negatively affected quality of life and has increased healthcare costs. The ASTRO TAVI registry included 14 centers and 16615 TAVR procedures between 2006 y 2021. In this period, there were 484 neurological events within<a href="https://solaci.org/en/2022/05/23/europcr-2022-astro-tavr-should-we-treat-post-tavr-strokes-with-neurointervention/" title="Read more" >...</a>
Edge-to-edge treatment of the mitral valve is currently a valid alternative to surgery in cases of mitral regurgitation. Different studies have taken residual mitral regurgitation as a parameter of success, but little research has been conducted on the residual gradient once the procedure has been completed. What has been published is that a mean gradient<a href="https://solaci.org/en/2022/05/19/is-high-mean-gradient-after-edge-to-edge-strategy-important/" title="Read more" >...</a>
Mitral valve prolapse is the most frequent cause of mitral valve regurgitation and is associated to hospitalization for cardiac failure and mortality. At present, the preferred treatment for operable patients is mitral valve surgical repair. Transcatheter edge to edge repair (TEER) has shown great benefit patients at high surgical risk; however, it has not been<a href="https://solaci.org/en/2022/05/12/transcatheter-edge-to-edge-repair-is-favorable-for-elderly-patients-at-high-surgical-risk/" title="Read more" >...</a>
In ST elevation MI, the common assessment methodology continues to the angiography; however, we all know it has certain limitations, especially when it comes to intermediate lesions or coronary dissections. Using imaging, especially high resolution such as OCT, has been looked into by some studies, but never randomized studies. The EROSION III is a randomized<a href="https://solaci.org/en/2022/05/10/should-we-start-using-oct-in-myocardial-infarction-with-non-obstructive-lesions/" title="Read more" >...</a>
Dear LATAM Fellows: We would like to tell you the Fellow’s Corner is coming back this year (FC). This is why we invite you once again to send us your cases on coronary artery, valve, peripheral and structural disease you might want to share with the entire SOLACI and ProEducar communities. As always, we plan to learn from each<a href="https://solaci.org/en/2022/04/28/fellows-corner-invitation-submit-your-case-and-lets-keep-learning-together/" title="Read more" >...</a>